FTC Gets More Time To Review Pfizer's $6.7B Arena Deal
Pfizer Inc. has resubmitted the notice for its planned $6.7 billion purchase of Arena Pharmaceuticals Inc., giving the Federal Trade Commission additional time to review the deal for its competitive impact....To view the full article, register now.
Already a subscriber? Click here to view full article